tirzepatide bmi Oral New Cleveland Clinic research finds

Unlike traditional weight loss medications that primarily target a single pathway, Zepbound works by activating both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors

If your ALT or AST levels change significantly, your prescribing provider should evaluate the context, considering whether you have baseline liver disease, how rapidly you are losing weight (rapid fat loss can temporarily increase liver enzyme release), and whether any concomitant medications could be contributing

Commenting on the case, Dr Solomon John, Consultant Surgeon at NMC Royal Hospital Sharjah, said: This case is a timely reminder that not every gastrointestinal symptom in patients taking GLP-1 receptor agonists should be assumed to be a routine medication side effect

This effect typically resolves as the body adapts to the compound and the reduced caloric intake